“
Verrica narrows This fall loss 72% year-over-year to -$0.51 per share as income surges 1,383% to $5.1M, although sequential income drops 65% from Q3.
Newsdesk · March 11, 2026
Loss narrows sharply. Verrica Prescription drugs (NASDAQ: VRCA) reported This fall 2025 adjusted lack of $0.51 per share, narrowing 71.7% from the year-ago lack of $1.81 per share. Income of $5.1 million surged multifold from $344,000 in This fall 2024, marking the biotechnology firm’s fourth consecutive quarter of year-over-year income progress. The corporate reported a GAAP internet lack of $8.1 million, or $0.57 per diluted share, in comparison with a lack of $16.2 million. Value of product income totaled $675,000 for the quarter.
Risky trajectory persists. The This fall outcomes cap an erratic fiscal 2025 for Verrica, with quarterly EPS swinging from a loss in Q1 to earnings in Q2 and Q3, earlier than returning to a lack of $0.51 in This fall. Income adopted a equally uneven path, climbing from $3.4 million in Q1 to peaks of $12.7 million and $14.3 million in Q2 and Q3, respectively, earlier than retreating sequentially to $5.1 million in This fall. Regardless of the quarter-to-quarter volatility, the year-over-year comparability exhibits significant progress. The corporate’s shares traded at $5.68 following the earnings report, throughout the 52-week vary of $3.28 to $9.82, on quantity of 271,185 shares.
